Stempoint Capital’s Edwards Lifesciences EW Stock Holding History

Stempoint Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,588	Closed	-$1.17M	–	92
2026 Q1	$1.17M	Buy	+14,588	New	+$1.2M	0.22%	65

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Stempoint Capital's EW Position: Q2 2026 in Review

Stempoint Capital sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 14,588 shares — an estimated $1.17M sold.

Stempoint Capital first reported a position in EW in Q1 2026 and held it in 1 quarter. The position peaked at $1.17M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Stempoint Capital reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
Stempoint Capital sold 14,588 Edwards Lifesciences shares in Q2 2026, an estimated $1.17M.
Stempoint Capital first reported a position in Edwards Lifesciences in Q1 2026 and held it in 1 quarter.
Stempoint Capital's Edwards Lifesciences position peaked at $1.17M in Q1 2026.
1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.